Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04475588
Other study ID # ITOLI-C19-02-I-00
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 1, 2020
Est. completion date July 7, 2020

Study information

Verified date June 2021
Source Biocon Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized, Parallel Group, Active Controlled Trial


Description:

This is a Multi-Centric, Open label, Two Arm Randomized, Phase 2 Study. All eligible patients entering into the study will be randomized in 2:1 ratio to receive the treatment A (Best supportive care + Itolizumab) / B (Best supportive care) respectively. Each patient will undergo the treatment based on their assigned treatment for a month along with battery of tests that includes, but not limited to, cytokines and chemokine, along with recording of TLC; DLC, ANC, ALC; Platelet count; S. creatinine; T.Bilirubin; morning Vitals -pulse, BP, RR; Temperature, PaO2/FiO2, MAP, GCS. As Itolizumab is an investigational drug, the benefit to COVID-19 patients experiencing complications such as Cytokine Release Syndrome is not known. However, findings from this study may be beneficial to the society at a large at the National and International Level.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date July 7, 2020
Est. primary completion date July 7, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Key Inclusion Criteria: 1. Male or female adults above 18 years (not tested in children yet) 2. Informed consent for participation in the study 3. Virological diagnosis of SARS-CoV2 infection (PCR) 4. Hospitalized due to clinical/instrumental diagnosis of COVID-19 infection 5. Oxygen saturation at rest in ambient air =94% 6. Patients who are in moderate to severe ARDS as defined by PaO2/Fio2 ratio of < 200 Key Exclusion Criteria: 1. Known severe allergic reactions to monoclonal antibodies 2. Active tuberculosis (TB) infection 3. History of inadequately treated tuberculosis or latent tuberculosis 4. In the opinion of the investigator,progression to death is highly probable, irrespective of the provision of treatments 5. Have received oral anti-rejection or immune-suppressive drugs within the past 6 months 6. Participating in other drug clinical trials (participation in COVID-19 anti-viral trials may be permitted if approved by Medical Monitor) 7. Pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination 8. Patients with known history of Hepatitis B, Hepatitis C or HIV 9. Absolute Neutrophils count (ANC) <1000 / mm3 10. Platelets <50,000 / mm3 11. Absolute Lymphocyte count (ALC): <500/mm3

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Itolizumab IV infusion
First dose of 1.6 mg/kg dose iv infusion, , investigator discretion to continue with 1.6 mg/kg dose every 2 weeks or 0.8 mg/kg weekly regimen up to 4 weeks. BSC: similar to Arm B
Best supportive care (BSC)
Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc

Locations

Country Name City State
India Seth GS Medical College and KEM Hospital Mumbai
India Topiwala National Medical College & B. Y. L. Nair Charitable Hospital, Mumbai
India All India Institute Of Medical Sciences New Delhi
India MAMC medical college and Lok Nayak Jai Prakash Narayan Hospital hospital New Delhi

Sponsors (1)

Lead Sponsor Collaborator
Biocon Limited

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary One-month Mortality Rate Between the Two Arms 1-month mortality is defined as the proportion of patients who met fatal outcome event by Day 30 One-month
Primary Lung Function Assessment - Proportion of the Patients With Stable or Improved SpO2 Without Increasing FiO2 Stable SpO2: Defined as number of patients with absence of increase in FiO2 to maintain SpO2 = 92% Improvement of SpO2: Defined as number of patients with decrease in FiO2 to maintain SpO2 > 92% Day 7, Day 14, Day 21 & Day 30
Primary Endo-tracheal Intubation/Invasive Mechanical Ventilation (IMV) Number of patients needing Intubation/IMV post treatment Day 30
Primary Reduction in Proportion of Patients on Non-invasive Ventilation Reduction in proportion of Patients on Non-invasive Ventilation: defined as number of patient improved and shifted to Face mask, Nasal cannula, non-rebreather mask or off oxygen over time Baseline (Day 1), Day 7, Day 14 Day 21 & Day 30
Primary Lung Function Assessment - Proportion of Patients With Stable PaO2 Without Increasing FiO2 Stable PaO2: Defined as number of patients with up to 10% change in PaO2/FiO2 ratio from baseline.
Improvement of PaO2: Defined as number of patients with > 10% improvement in PaO2/FiO2 ratio from baseline (including patients weaned off oxygen).
Day 7, Day14, Day 21 & Day30
Primary Reduction in Proportion of Patients- Invasive Mechanical Ventilation Patient improved from invasive ventilation over time from baseline. Day7, Day14, Day21 & Day 30
Primary Reduction in Proportion of Patients-High Flow Nasal Oxygen Patient improved from High Flow Nasal Oxygen over time from baseline. Day7 ,Day 14 ,Day 21, Day 30
Primary Mean Change From Baseline in Ferritin Mean Change from Baseline in Ferritin Day 7, Day 14, Day 21 & Day 30
Primary Mean Change From Baseline in LDH Mean Change from Baseline in LDH Day 7, Day14, Day 21 and Day 30.
Primary Mean Change From Baseline in CRP (C-reactive Protein) Mean Change from Baseline in CRP Day 7, Day 14, Day 21 & Day 30
Primary Mean Change From Baseline D-Dimer Day 7, Day 14, Day 21 & Day 30
Secondary Mean Change From Baseline of Absolute Lymphocyte Count Mean change From baseline in Lymphocyte count day 7, day 14 ,day 21 & day 30
Secondary Biomarkers (IL-6, TNF-a) Mean values of Pre and Post 1st and 2nd dose are shown Pre and Post 1st dose; Pre and Post 2nd dose
Secondary Mean PaO2 (Partial Pressure of Oxygen) / FiO2 (Fraction of Inspired Oxygen, FiO2) Ratio (or P/F Ratio) Mean PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) Baseline, Day 7, Day 14, Day 21 & Day 30
Secondary Number and Percentage of Patients With Radiological Response Number of patients with improved X ray/CT findings as compared to baseline or returned to normal in the last assessment up to Day 30
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3